Related references
Note: Only part of the references are listed.Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study
Farzin Khosrow-Khavar et al.
ANNALS OF THE RHEUMATIC DISEASES (2022)
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis
Steven R. Ytterberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Risk of venous thromboembolism associated with tofacitinib in patients with rheumatoid arthritis: a population-based cohort study
Rishi J. Desai et al.
RHEUMATOLOGY (2022)
Regulatory T cell frequencies in patients with rheumatoid arthritis are increased by conventional and biological DMARDs but not by JAK inhibitors
Anja Meyer et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial
Rene Westhovens et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial
Bernard Combe et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib
Paqui G. Traves et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Lymphocyte modulation by tofacitinib in patients with rheumatoid arthritis
Natasa Isailovic et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2021)
JAK inhibitors: Ten years after
Francesca Romana Spinelli et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2021)
JAK1: Number one in the family; number one in inflammation?
Francesca Romana Spinelli et al.
RHEUMATOLOGY (2021)
Impact of Different JAK Inhibitors and Methotrexate on Lymphocyte Proliferation and DNA Damage
Annika Reddig et al.
JOURNAL OF CLINICAL MEDICINE (2021)
Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus
Sarfaraz A. Hasni et al.
NATURE COMMUNICATIONS (2021)
Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitors-A Strategy for Hematological Malignancies?
Klara Klein et al.
CANCERS (2021)
Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme
Stanley B. Cohen et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement
Peter Nash et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
JAK inhibitors alter NK cell functions and may impair immunosurveillance against lymphomagenesis
Gaetane Nocturne et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2020)
The Janus Kinase inhibitor tofacitinib impacts human dendritic cell differentiation and favours M1 macrophage development
Romaine Stalder et al.
EXPERIMENTAL DERMATOLOGY (2020)
Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: Perspectives for scleroderma-associated interstitial lung disease
Alain Lescoat et al.
BIOCHEMICAL PHARMACOLOGY (2020)
JAK inhibitors impair GM-CSF-mediated signaling in innate immune cells
Yuya Fujita et al.
BMC IMMUNOLOGY (2020)
SnapShot: JAK-STAT Signaling II
Alejandro V. Villarino et al.
CELL (2020)
Complex Autoinflammatory Syndrome Unveils Fundamental Principles of JAK1 Kinase Transcriptional and Biochemical Function
Conor N. Gruber et al.
IMMUNITY (2020)
Filgotinib, a JAK1 Inhibitor, Modulates Disease-Related Biomarkers in Rheumatoid Arthritis: Results from Two Randomized, Controlled Phase 2b Trials
Jacqueline M. Tarrant et al.
RHEUMATOLOGY AND THERAPY (2020)
Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan
Tsutomu Takeuchi et al.
ARTHRITIS RESEARCH & THERAPY (2020)
Janus kinases to jakinibs: from basic insights to clinical practice
Massimo Gadina et al.
RHEUMATOLOGY (2019)
Tofacitinib modulates the VZV-specific CD4+ T cell immune response in vitro in lymphocytes of patients with rheumatoid arthritis
Giovanni Almanzar et al.
RHEUMATOLOGY (2019)
Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial
Mark C. Genovese et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Tofacitinib inhibits ox-LDL-induced adhesion of THP-1 monocytes to endothelial cells
Xiaoyang Yang et al.
ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY (2019)
Peficitinib Inhibits the Chemotactic Activity of Monocytes via Proinflammatory Cytokine Production in Rheumatoid Arthritis Fibroblast-Like Synoviocytes
Yuzo Ikari et al.
CELLS (2019)
The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors
Katie Bechman et al.
PHARMACOLOGICAL RESEARCH (2019)
Evaluation of the Short-, Mid-, and Long-Term Effects of Tofacitinib on Lymphocytes in Patients With Rheumatoid Arthritis
Ronald van Vollenhoven et al.
ARTHRITIS & RHEUMATOLOGY (2019)
JAK Inhibition Differentially Affects NK Cell and ILC1 Homeostasis
Laura Vian et al.
FRONTIERS IN IMMUNOLOGY (2019)
Safety and efficacy of tofacitinib for up to 9.5years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study
Juergen Wollenhaupt et al.
ARTHRITIS RESEARCH & THERAPY (2019)
Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations
Iain B. McInnes et al.
ARTHRITIS RESEARCH & THERAPY (2019)
Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition
Martin E. Dowty et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2019)
Jak3 deficiency blocks innate lymphoid cell development
M. L. Robinette et al.
MUCOSAL IMMUNOLOGY (2018)
Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteers
Kent J. Weinhold et al.
CLINICAL IMMUNOLOGY (2018)
The JAK inhibitor ruxolitinib reduces inflammation in an ILC3-independent model of innate immune colitis
A. M. Overstreet et al.
MUCOSAL IMMUNOLOGY (2018)
Janus Kinase inhibitor Baricitinib Modulates human innate and adaptive immune system
Satoshi Kubo et al.
FRONTIERS IN IMMUNOLOGY (2018)
Characterization and Changes of Lymphocyte Subsets in Baricitinib-Treated Patients With Rheumatoid Arthritis An Integrated Analysis
Yoshiya Tanaka et al.
ARTHRITIS & RHEUMATOLOGY (2018)
Tofacitinib inhibits granulocyte-macrophage colony-stimulating factor-induced NLRP3 inflammasome activation in human neutrophils
Makiko Yashiro Furuya et al.
ARTHRITIS RESEARCH & THERAPY (2018)
In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)
Julie M. Parmentier et al.
BMC RHEUMATOLOGY (2018)
Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study
Maxime Dougados et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Analysis of haematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase 3 and long-term extension studies
Hendrik Schulze-Koops et al.
RHEUMATOLOGY (2017)
Impact of tofacitinib treatment on human B-cells in vitro and in vivo
Marta Rizzi et al.
JOURNAL OF AUTOIMMUNITY (2017)
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
Peter C. Taylor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Peficitinib, a JAK Inhibitor, in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate
A. J. Kivitz et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis
Mark C. Genovese et al.
ARTHRITIS & RHEUMATOLOGY (2017)
2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty
Susan M. Goodman et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Janus kinase inhibitors prevent migration of rheumatoid arthritis neutrophils towards interleukin-8, but do not inhibit priming of the respiratory burst or reactive oxygen species production
T. S. Mitchell et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2017)
Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study
Tsutomu Takeuchi et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases
Daniella M. Schwartz et al.
NATURE REVIEWS RHEUMATOLOGY (2016)
Targeting JAK kinase in solid tumors: emerging opportunities and challenges
M. Buchert et al.
ONCOGENE (2016)
Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study
Yoshiya Tanaka et al.
JOURNAL OF RHEUMATOLOGY (2016)
Baricitinib in Patients with Refractory Rheumatoid Arthritis
Mark C. Genovese et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Inhibition of JAK3 and PKC via Immunosuppressive Drugs Tofacitinib and Sotrastaurin Inhibits Proliferation of Human B Lymphocytes In Vitro
M. N. Martina et al.
TRANSPLANTATION PROCEEDINGS (2016)
Biallelic JAK1 mutations in immunodeficient patient with mycobacterial infection
Davide Eletto et al.
NATURE COMMUNICATIONS (2016)
Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Mark C. Genovese et al.
ARTHRITIS & RHEUMATOLOGY (2016)
A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy
Joel M. Kremer et al.
ARTHRITIS & RHEUMATOLOGY (2016)
Human TYK2 deficiency: Mycobacterial and viral infections without hyper-IgE syndrome
Alexandra Y. Kreins et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
Intestinal Epithelial Cell Tyrosine Kinase 2 Transduces IL-22 Signals To Protect from Acute Colitis
Eva Hainzl et al.
JOURNAL OF IMMUNOLOGY (2015)
The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells
Satoshi Kubo et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Tofacitinib, a JAK inhibitor, inhibits human B cell activation in vitro
Sheau-Pey Wang et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
PHARMACODYNAMICS OF A NOVEL JAK1 SELECTIVE INHIBITOR IN RAT ARTHRITIS AND ANEMIA MODELS AND IN HEALTHY HUMAN SUBJECTS
J. Voss et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Triazolopyridines as Selective JAK1 Inhibitors: From Hit Identification to GLPG0634
Christel J. Menet et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Fate of Lymphocytes after Withdrawal of Tofacitinib Treatment
Elisa Piscianz et al.
PLOS ONE (2014)
Effects of tofacitinib on lymphocytes in rheumatoid arthritis: relation to efficacy and infectious adverse events
Koshiro Sonomoto et al.
RHEUMATOLOGY (2014)
A Restricted Role for TYK2 Catalytic Activity in Human Cytokine Responses Revealed by Novel TYK2-Selective Inhibitors
Sue J. Sohn et al.
JOURNAL OF IMMUNOLOGY (2013)
Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases
Luc Van Rompaey et al.
JOURNAL OF IMMUNOLOGY (2013)
MECHANISMS OF DISEASE JAKs and STATs in Immunity, Immunodeficiency, and Cancer
John J. O'Shea et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells
Keisuke Maeshima et al.
ARTHRITIS AND RHEUMATISM (2012)
Impaired Dendritic Cell Proinflammatory Cytokine Production in Psoriatic Arthritis
Mark H. Wenink et al.
ARTHRITIS AND RHEUMATISM (2011)
JAK3 Specific Kinase Inhibitors: When Specificity Is Not Enough
Luk Cox et al.
CHEMISTRY & BIOLOGY (2011)
Jak1 Has a Dominant Role over Jak3 in Signal Transduction through γc-Containing Cytokine Receptors
Claude Haan et al.
CHEMISTRY & BIOLOGY (2011)
Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)
Kamran Ghoreschi et al.
JOURNAL OF IMMUNOLOGY (2011)
Meta-analysis of TYK2 gene polymorphisms association with susceptibility to autoimmune and inflammatory diseases
Jin-Hui Tao et al.
MOLECULAR BIOLOGY REPORTS (2011)
MECHANISMS OF DISEASE The Pathogenesis of Rheumatoid Arthritis
Iain B. McInnes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050
Jordan S. Fridman et al.
JOURNAL OF IMMUNOLOGY (2010)
Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis
Debra M. Meyer et al.
JOURNAL OF INFLAMMATION-LONDON (2010)
Influence of Membrane CD25 Stability on T Lymphocyte Activity: Implications for Immunoregulation
Todd M. Brusko et al.
PLOS ONE (2009)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Historical review: Cytokines as therapeutics and targets of therapeutics
J Vilcek et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2004)
Routes to transplant tolerance versus rejection: The role of cytokines
PT Walsh et al.
IMMUNITY (2004)
Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor
PS Changelian et al.
SCIENCE (2003)
Share Paper
